Virginia Retirement Systems ET AL Buys 18,500 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Virginia Retirement Systems ET AL boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 1.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,169,800 shares of the biopharmaceutical company’s stock after purchasing an additional 18,500 shares during the period. Bristol-Myers Squibb comprises about 0.6% of Virginia Retirement Systems ET AL’s portfolio, making the stock its 29th largest holding. Virginia Retirement Systems ET AL owned 0.07% of Bristol-Myers Squibb worth $53,050,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc grew its position in Bristol-Myers Squibb by 5.9% in the fourth quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock valued at $445,300,000 after purchasing an additional 474,820 shares in the last quarter. Lodestar Investment Counsel LLC IL grew its position in Bristol-Myers Squibb by 5.2% in the second quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after purchasing an additional 5,579 shares in the last quarter. Perella Weinberg Partners Capital Management LP grew its position in Bristol-Myers Squibb by 10.9% in the first quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 1,905 shares in the last quarter. Stephens Inc. AR grew its position in Bristol-Myers Squibb by 30.7% in the first quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock valued at $10,331,000 after purchasing an additional 50,798 shares in the last quarter. Finally, Nachman Norwood & Parrott Inc lifted its stake in Bristol-Myers Squibb by 3.5% in the second quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after acquiring an additional 1,687 shares during the last quarter. 77.71% of the stock is owned by institutional investors and hedge funds.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 5,000 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was acquired at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the purchase, the director now directly owns 27,000 shares of the company’s stock, valued at $1,276,830. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Bertolini acquired 11,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, with a total value of $491,920.00. Following the purchase, the director now directly owns 11,397 shares in the company, valued at $509,673.84. The disclosure for this purchase can be found here. Company insiders own 0.13% of the company’s stock.

Shares of NYSE BMY traded up $0.07 during mid-day trading on Tuesday, reaching $45.45. 714,169 shares of the company were exchanged, compared to its average volume of 14,899,019. The firm’s 50-day moving average is $45.55. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The company has a market capitalization of $74.30 billion, a PE ratio of 11.42, a P/E/G ratio of 2.28 and a beta of 0.73. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.12. The company had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. Bristol-Myers Squibb’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.01 EPS. As a group, analysts expect that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.61%. The ex-dividend date was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

A number of brokerages have commented on BMY. Argus cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target for the company. in a research note on Monday, May 20th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Tuesday, May 7th. BMO Capital Markets increased their price target on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Goldman Sachs Group began coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, May 28th. They issued a “buy” rating and a $54.00 price target for the company. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $55.45.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: The mechanics of the bid-ask spread in trading

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.